Karyopharm Therapeutics Inc. Quarterly Net Cash Provided by (Used in) Financing Activities in USD from Q1 2018 to Q1 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Karyopharm Therapeutics Inc. annual/quarterly Net Cash Provided by (Used in) Financing Activities history and growth rate from Q1 2018 to Q1 2023.
  • Karyopharm Therapeutics Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending March 31, 2023 was $0.000, a 100% decline year-over-year.
  • Karyopharm Therapeutics Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $1.12M, a 99.4% decline from 2022.
  • Karyopharm Therapeutics Inc. annual Net Cash Provided by (Used in) Financing Activities for 2022 was $194M, a 163% increase from 2021.
  • Karyopharm Therapeutics Inc. annual Net Cash Provided by (Used in) Financing Activities for 2021 was $73.6M, a 57.2% decline from 2020.
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2023 $0 -$30.8M -100% Jan 1, 2023 Mar 31, 2023 10-Q 2023-05-04
Q1 2022 $30.8M +$20.1M +188% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q1 2021 $10.7M -$154M -93.5% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q1 2020 $165M +$165M +108340% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-04
Q1 2019 $152K -$277K -64.6% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-05
Q1 2018 $429K Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.